[1] After completing his Ph.D., Rosenfeld began working in translational research within Rosetta Genomics Ltd, a leading company in microRNA-based diagnostic tests for cancer.
Within his first year, his laboratory became one of the few worldwide to obtain accurate data on circulating tumour DNA (ctDNA) in patient plasma.
[7] Their key publication in the New England Journal of Medicine demonstrated the advantages of ctDNA over other biomarkers, notably circulating tumor cells.
His citation on election reads: "Nitzan Rosenfeld is a Senior Group Leader at Cancer Research UK Cambridge Institute.
He has developed multiple clinical diagnostic tests for cancer, based on microRNA expression profiling and on circulating cell-free tumour DNA in plasma.